Table 1.
Baseline demographics for the per protocol analysis group (n=53).
| Parameters | Results, n (%) | ||
| Gender |
|
||
|
|
Male | 30 (56.6) | |
|
|
Female | 23 (43.4) | |
| Age (years) | 60.4 (11.8)a | ||
| Weight (kg) | 64 (16.8)a | ||
| FEV1b (%) | 43 (16)a | ||
| FEV1 (L) | 1.01 (0.42)a | ||
| Reversibility (%) | 13 (6)a | ||
| History of a hospitalization or emergency department visit in the last year | 37 (69.8) | ||
| FeNOc (ppb) | 12.1 (6)a | ||
| Peripheral eosinophil (%) | 4 (3)a | ||
| GINAd asthma control score | 3.0 (0.8)a | ||
| Uncontrolled asthma with frequent rescue medication use | 53 (100) | ||
| Prior pMDIe use | 16 (30.2) | ||
| Prior DPIf use | 37 (69.8) | ||
| Oral xanthine use | 33 (62.3) | ||
| Comorbidities |
|
||
|
|
Hypertension | 21 (39.6) | |
|
|
ASCVDg | 3 (5.7) | |
|
|
Bronchiectasis | 5 (9.4) | |
|
|
ARDSh | 5 (9.4) | |
|
|
Atopy | 5 (9.4) | |
| Treatment |
|
||
|
|
Nebulized glycopyrronium/formoterol/budesonide (25/20/500 mcg) | 40 (75.5) | |
| Nebulized formoterol/budesonide (20/500 mcg) | 13 (24.5) | ||
aMean (SD).
bFEV1: forced expiratory volume in one second.
cFeNO: fractional exhaled nitric oxide.
dGINA: Global Initiative for Asthma.
epMDI: pressurized meter dose inhaler.
fDPI: dry powder inhaler.
gASCVD: atherosclerotic cardiovascular disease.
hARDS: acute respiratory distress syndrome.